Variant generation and selection: an in vitro model of tumor progression
- PMID: 6706435
- DOI: 10.1002/ijc.2910330419
Variant generation and selection: an in vitro model of tumor progression
Abstract
Evidence for a new in vitro model of tumor progression was sought on the basis of the variant generation and selection hypothesis. The stability of a cloned murine tumor was examined during growth in standard tissue culture or in media containing the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Analysis of subclones from the appropriate tumor populations revealed that growth of the L5178Y-F9 clone in 100 ng/ml TPA and 0.1% dimethyl sulphoxide (DMSO) for 2 days yielded a tumor which exhibited increased cellular heterogeneity for susceptibility to both syngeneic and allogeneic natural antibodies (NAb). Subsequent exposure of TPA- and DMSO-treated cells to two cycles of syngeneic NAb-mediated cytolysis resulted in tumor populations which expressed a reduced sensitivity to syngeneic NAb. Thus the elements of tumor variant generation and selection were demonstrated by means of this approach, and repeated cycles of the TPA treatment and NAb cytolysis produced tumor cells with a reduced susceptibility not only to NAb in vitro but also to anti-tumor natural resistance (NR) measured in a tumor elimination assay in vivo. These observations extend the support for the notion that tumor progression can proceed through variant generation and selection. Furthermore, the association of tumor variant generation with exposure to the combination of TPA and DMSO, both non-mutagens, offers a model for studying non-mutagenic mechanisms of tumor development.
Similar articles
-
Tumor progression in vitro: tumor-promoter-induced reversible decrease in natural immune susceptibility.Carcinogenesis. 1988 Nov;9(11):1967-73. doi: 10.1093/carcin/9.11.1967. Carcinogenesis. 1988. PMID: 3180334
-
In vivo generation and selection of variants with altered sensitivity to natural resistance (NR): a model of tumor progression.Int J Cancer. 1983 Jan 15;31(1):99-105. doi: 10.1002/ijc.2910310116. Int J Cancer. 1983. PMID: 6832850
-
Characterization of tumor progression from threshold tumor inocula: evidence for natural resistance.Int J Cancer. 1985 Mar 15;35(3):385-93. doi: 10.1002/ijc.2910350315. Int J Cancer. 1985. PMID: 3972473
-
Tumor progression in vitro: the paradoxical natural antibody and complement-selected phenotype.Nat Immun Cell Growth Regul. 1987;6(4):189-204. Nat Immun Cell Growth Regul. 1987. PMID: 3683415
-
Tumor selection in vivo for reduced sensitivity to natural resistance and natural antibodies.J Natl Cancer Inst. 1984 Feb;72(2):339-46. J Natl Cancer Inst. 1984. PMID: 6582320
Cited by
-
Implications of tumor progression on clinical oncology.Clin Exp Metastasis. 1985 Jul-Sep;3(3):151-88. doi: 10.1007/BF01786761. Clin Exp Metastasis. 1985. PMID: 3902300 Review. No abstract available.
-
Loss of intercellular junctional communication correlates with metastatic potential in mammary adenocarcinoma cells.Proc Natl Acad Sci U S A. 1988 Jan;85(2):473-6. doi: 10.1073/pnas.85.2.473. Proc Natl Acad Sci U S A. 1988. PMID: 3422438 Free PMC article.
-
Characterization of the progressive sublines derived from a weakly malignant cloned cell line, ER-1, co-inoculated subcutaneously with a foreign body.Clin Exp Metastasis. 1998 Apr;16(3):291-8. doi: 10.1023/a:1006505211766. Clin Exp Metastasis. 1998. PMID: 9568647
-
The value of multisequence MR in the morphological evaluation of peripheral lung cancer.BMC Med Imaging. 2025 May 21;25(1):178. doi: 10.1186/s12880-025-01726-w. BMC Med Imaging. 2025. PMID: 40399835 Free PMC article.
-
FcR may function as a progression factor of nonlymphoid tumors.Immunol Res. 1992;11(3-4):283-95. doi: 10.1007/BF02919134. Immunol Res. 1992. PMID: 1287122 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous